Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Open-angle glaucoma is a degeneration of the optic nerve, highlighted by campimetric
alterations, and wose only current therapeutic target is the lowering of the intra-ocular
pressure (using eye drops, surgery or laser). MEMOPTIC is a tablet combining citicoline,
magnesium and Gingko biloba, which have a neuroprotective effect already used in
neurodegenerative diseases such as Alzheimer's disease for example. Citicoline has also shown
several promising results in ophthalmological diseases (glaucoma, amblyopia or more recently
in ischemic optic neuropathies). The citicoline used in eye drops (NEURODROP) has already
shown results on the preservation of the vision of glaucomatous patients.
The purpose of this project is to determine if MEMOPTIC can have an effect, in addition to
the conventional treatments, in the preservation of vision of patients treated for an
open-angle glaucoma.